Separating the cost of biopharmaceutical research and development from the final market price of medicines would misalign incentives, raise bureaucratic costs, and limit innovation.
We don’t want to die poor: that’s how creatives feel about pending copyright changes Artists, writers and musicians stand to lose significant income if laws are changed, while Big Tech will be the big winner
The WHO is most effective when it unites nations around practical solutions, rather than dividing them in ideological debates. Next week in Geneva the Executive Board needs to steady the ship. WHO’s proper role should to be to set the top priorities for global health, and not try to be all things to all people. WHO must get back to basics, and put politics to one side.
This post is one of a series in the #Innovate4Health policy research initiative. For centuries, people have been fascinated with and assisted by wearable technology.
Saudi Arabia thus shows that healthcare innovation happens throughout the world. The work of Saudi entrepreneurs holds promise for solving both economic and health challenges in the Kingdom.
Global health agency Unitaid has helped millions in low- and middle-income countries through its constructive and collaborative approach to intellectual property rights (IPRs).
According to a major study in Lancet, India has made solid progress in reducing deaths from common non-communicable diseases, such as cancer,
This report argues that intellectual property rights (IPRs) are key to ASEAN development. It is a collaboration between five think tanks from four ASEAN countries.
Improving access to medicines and quality healthcare remains a key area of action for the member states of the United Nations.